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Abstract: BACKGROUND Sex differences with regard to clinical manifestations and response to tumor
necrosis factor inhibitors (TNFi) have been delineated for the radiographic form of axial spondyloarthritis
(axSpA). More limited evidence for a differential effectiveness of treatment in genders exists for the
nonradiographic disease state (nr-axSpA). The aim of the study was to compare demographics, clinical
parameters, and response to TNFi in women versus men with nr-axSpA. METHODS We compared disease
characteristics of 264 women and 231 men with nr-axSpA at inclusion in the prospective Swiss Clinical
Quality Management Cohort. Response to a first TNFi was assessed in 85 women and 78 men without
diagnosed co-morbid fibromyalgia. The primary outcome was the proportion of patients achieving the
40% improvement in the Assessment of SpondyloArthritis international Society criteria (ASAS40) at 1
year. Additional response outcomes were evaluated as secondary outcomes. Patients having discontinued
TNFi were considered non-responders. Logistic regression analyses were adjusted for baseline differences,
which might potentially mediate the effect of sex on treatment response. RESULTS Compared to men,
women had a longer diagnostic delay, a higher level of perceived disease activity, and more enthesitis
and were in a lower percentage HLA-B27 positive. An ASAS40 response was achieved by 17% of women
and 38% of men (OR 0.34; 95% CI 0.12, 0.93; p = 0.02). A significantly lower response rate in women
was confirmed in the adjusted analysis (OR 0.19; 95% CI 0.05, 0.62; p = 0.009) as well as for the
other outcomes assessed. CONCLUSION Despite only few sex differences in patient characteristics in
nr-axSpA, response rates to TNFi are significantly lower in women than in men.
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Abstract
Background: Sex differences with regard to clinical manifestations and response to tumor necrosis factor inhibitors
(TNFi) have been delineated for the radiographic form of axial spondyloarthritis (axSpA). More limited evidence for a
differential effectiveness of treatment in genders exists for the nonradiographic disease state (nr-axSpA). The aim of
the study was to compare demographics, clinical parameters, and response to TNFi in women versus men
with nr-axSpA.
Methods: We compared disease characteristics of 264 women and 231 men with nr-axSpA at inclusion in the
prospective Swiss Clinical Quality Management Cohort. Response to a first TNFi was assessed in 85 women
and 78 men without diagnosed co-morbid fibromyalgia. The primary outcome was the proportion of patients
achieving the 40% improvement in the Assessment of SpondyloArthritis international Society criteria (ASAS40)
at 1 year. Additional response outcomes were evaluated as secondary outcomes. Patients having discontinued
TNFi were considered non-responders. Logistic regression analyses were adjusted for baseline differences,
which might potentially mediate the effect of sex on treatment response.
Results: Compared to men, women had a longer diagnostic delay, a higher level of perceived disease activity, and
more enthesitis and were in a lower percentage HLA-B27 positive. An ASAS40 response was achieved by 17% of
women and 38% of men (OR 0.34; 95% CI 0.12, 0.93; p = 0.02). A significantly lower response rate in women was
confirmed in the adjusted analysis (OR 0.19; 95% CI 0.05, 0.62; p = 0.009) as well as for the other outcomes assessed.
Conclusion: Despite only few sex differences in patient characteristics in nr-axSpA, response rates to TNFi are significantly
lower in women than in men.
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Background
With the introduction of the Assessment of Spondy-
loArthritis international Society (ASAS) classification
criteria [1], patients with axial spondyloarthritis
(axSpA) can be classified as having radiographic or
nonradiographic disease (r-axSpA vs. nr-axSpA), de-
pending on the presence or absence of definite radio-
graphic sacroiliac changes according to the modified
New York criteria [2], respectively [3]. There is ample
evidence that, from a clinical point of view, patients
with nr-axSpA have a similar disease burden when
compared with patients with r-axSpA [4–9]. The latter
is, however, associated with a higher propensity to
osteoproliferation potentially leading to spinal ankylosis
and a greater impairment of spinal mobility [10, 11].
While a male predominance is found in r-axSpA, an
equal male to female distribution has repeatedly been
reported for nr-axSpA. Some important differences in
clinical manifestations and response to treatment be-
tween the sexes have been delineated for the radio-
graphic disease form [12–19]. In comparison to men,
women with r-axSpA present with higher self-reported
disease activity and functional impairment, a lower
quality of life, less severe spinal radiographic changes,
and more peripheral disease (arthritis and enthesitis).
Objective markers of inflammation, such as elevated C-
reactive protein (CRP) levels and magnetic resonance
imaging (MRI) inflammation of the axial skeleton are
more often found in men. It remains unclear, whether
comparable differences between the sexes exist for nr-
axSpA. Indeed, available data on gender differences in
nr-axSpA is limited to subgroups (e.g., clinical arm of
the ASAS classification criteria) [20]. Following the
demonstration of response to tumor necrosis factor in-
hibitors (TNFi) also in active nr-axSpA following an in-
adequate response to nonsteroidal anti-inflammatory
drugs (NSAIDs) [21–24], this subgroup of patients has
been included in recent recommendations for the treat-
ment of axSpA with biologic disease-modifying anti-
rheumatic drugs (bDMARDs) [25, 26]. There exists some
evidence for a differential effectiveness of treatment in
female versus male patients with nr-axSpA [8, 27]. The
aim of this study was to compare male and female patients
classified as having nr-axSpA with regard to demograph-
ics, clinical manifestations and response to tumor necrosis




Patients with a clinical diagnosis of axSpA in the Swiss
Clinical Quality Management (SCQM) cohort [6] were
included in the current study if they met the following
conditions: (a) fulfillment of the Assessment of
SpondyloArthritis international Society (ASAS) classifi-
cation criteria for axSpA [1] and (b) lack of definite
radiographic sacroiliac changes according to the modi-
fied New York criteria [2]. The latter was assessed on
collected radiographs of the pelvis, which were centrally
digitized, and independently scored in a blinded matter
by 2 rotating members of the SCQM axSpA scientific
board (a total of 6 calibrated readers) [6]. Discrepancies
between 2 readers in the evaluation of the sacroiliac
joints were solved by consensus. Data on sacroiliac or
spinal magnetic resonance imaging (MRI) scan positivity
for inflammation was entered in the online database by
the treating rheumatologist at each visit (expert opinion
of local rheumatologist or radiologist; no central MRI
scoring performed, as MRI scans were not collected).
Clinical evaluations were recommended at inclusion in
the cohort, at yearly intervals thereafter, as well as at
treatment changes and were performed according to the
recommendations of ASAS [28]. Enthesitis was assessed
with the Maastricht Ankylosing Spondylitis Enthesitis
Score (MASES), modified to include the proximal inser-
tion of the plantar fasciae. Rheumatologists indicate the
presence of enthesitis by clicking on the specified enthe-
sitis location on a homunculus shown from front and
back. The rheumatologist is reminded of the intensity of
the pressure to test for enthesitis with a written note ad-
jacent to the homunculus: “thumb pressure of approxi-
mately 4 kg, corresponding to the pressure leading to
discoloration of a third of the thumbnail.”
The diagnosis of concurrent fibromyalgia was based
on the expert opinion of the treating rheumatologist and
reported through a comorbidity questionnaire. The
rheumatologist is automatically led through the comor-
bidity questionnaire in the online database at the time of
reporting the results of the clinical examination to en-
sure systematic completion of the form. The proportion
of the population with available data on comorbidities
was 62%. The fulfillment of classification criteria for
fibromyalgia was not required and no standardized fibro-
myalgia questionnaire was used.
Data on patients recruited into SCQM from January
2005 to November 2018 were available for the current
analysis. The Ethics committee of the Canton of Zurich
(KEK-ZH-Nr. 2014-0439) approved the study and writ-
ten informed consent was obtained from all patients
prior to inclusion into SCQM.
Treatment effectiveness
Assessment of response to treatment with a first TNFi
was analyzed in patients with available information on
disease activity at start of treatment, as well as with an
available outcome at 1 year (± 6 months). Patients with
concomitant fibromyalgia were excluded from the ana-
lyses if this feature was reported either at baseline or at
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any time-point during follow-up. Given the fact the pa-
tients treated with biologics are preferentially included
in SCQM, we expected a lower proportion of patients
with fibromyalgia in comparison to other studies, assum-
ing that rheumatologists might be reluctant to install bi-
ologics in axSpA patients diagnosed with concurrent
fibromyalgia.
Response was either assessed in patients still on treat-
ment at this time-point (completer analysis) or in all pa-
tients—with those having discontinued treatment in the
meantime being considered non-responders (response/tol-
erance analysis) [18]. The achievement of the 40% im-
provement ASAS criteria (ASAS40) was considered as the
primary outcome. We also analyzed additional response
rates: ASAS20 response criteria, the proportion of patients
achieving an Ankylosing Spondylitis Disease Activity
Score (ASDAS) < 2.1 or an ASDAS < 1.3 (remission), as
well as a clinically important and major improvements in
ASDAS. It is important to note that the majority of TNFi
(adalimumab, etanercept, golimumab and infliximab) are
approved for the treatment of “Bechterew’s” disease after
inadequate response to conventional treatment in
Switzerland, with no differentiation being made in the
label between the radiographic and the nonradiographic
disease form. The label for certolizumab-pegol differs in
this respect. It is approved in Switzerland for the treat-
ment of severe active axial spondyloarthritis, including pa-
tients with severe active ankylosing spondylitis as well as
severe active nr-axSpA, if the patients have inadequately
responded to conventional treatment or had experienced
adverse events to nonsteroidal anti-rheumatic drugs.
Moreover, patients with severe active nr-axSpA requiring
certolizumab-pegol should present with objective signs of
inflammation (either on MRI or an elevated C-reactive
protein (CRP)).
Statistical analyses
Comparisons between baseline characteristics in women
and men were performed using the Fisher’s exact test
for categorical variables and the Mann-Whitney U test
for continuous variables. The Fisher’s exact test was used
to assess the significance of differences in response rates
between genders. An adjusted odds ratio for different re-
sponse criteria was estimated through logistic regression
analysis. The following variables were included in the
models as they differed between men and women at
start of treatment and could potentially be mediators of
the effect of sex on treatment response: diagnostic delay,
degree of enthesitis, the level of the Bath Ankylosing
Spondylits Disease Activity Index (BASDAI), and the
body mass index (BMI). Drug retention was assessed
with Kaplan-Meier plots and differences in retention
rates were analyzed with the log-rank test. All tests were
2-sided (significance level set at 0.05). R statistical soft-
ware was utilized for all analyses.
Results
Baseline characteristics
From a total of 1818 patients fulfilling the ASAS classifi-
cation criteria with an available baseline pelvis radio-
graph, 495 patients presented without definite sacroiliac
changes according to central scoring and were included
as nr-axSpA in the current study (231 men and 264
women). Baseline characteristics of these patients are
shown in Table 1 (A). Women were slightly older at in-
clusion, which was mainly due to a significantly longer
diagnostic delay, as the age at symptom onset was com-
parable between the genders. In comparison to men, a
slightly lower proportion of women was HLA-B27 posi-
tive (67.0% vs. 76.5%, p = 0.03). Mean ± SD disease activ-
ity as assessed by the BASDAI was higher in women
than in men (5.3 ± 2.1 vs. 4.6 ± 2.2, p = 0.003). CRP levels
and the proportion of patients with elevated CRP were
comparable between the sexes, as was the ASDAS.
Moreover, there were no differences with regards to
impairment of physical function (BASFI), spinal mo-
bility (BASMI), and of quality of life (EQ-5D). Re-
garding peripheral manifestations, the proportion of
men and women with peripheral arthritis and dactyli-
tis was comparable. However, female nr-axSpA pa-
tients presented more often with peripheral enthesitis
and with a higher MASES. The proportion of patients
with concomitant clinically diagnosed fibromyalgia
was higher in women than in men (13.1% vs. 2.7%,
p < 0.001). After excluding patients with diagnosed
concurrent fibromyalgia from the analyses, remaining
gender differences in BASDAI were mainly due to fa-
tigue and enthesitis, both more prominent in women
than in men (Table 1 (B)). Further comparisons did
not reveal any sex differences with regards to extra-
skeletal manifestations (uveitis, psoriasis, or inflamma-
tory bowel disease), smoking status, education, and
work absenteeism. The only additional difference be-
tween the sexes concerned the BMI (24.1 vs. 25.6 on
average for women and men, respectively).
Response to TNFi treatment
Treatment response was investigated in nr-axSpA pa-
tients without concomitant fibromyalgia. A first TNFi
was initiated in 163 patients (Table 2). Corresponding to
sex differences seen in the whole nr-axSpA cohort,
women starting treatment had a longer diagnostic delay,
higher BASDAI and MASES, and a lower BMI in com-
parison to men. The proportion of women initiating
TNFi at an ASDAS level > 2.1 was 96.2%, while it was
only 83.9% in men (p = 0.02). A follow-up visit at 1 year
to assess treatment response was available in 120
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Table 1 Characteristics of all patients classified as having nonradiographic axial spondyloarthritis at inclusion in SCQM











Age, years 495 36.6 (10.9) 38.2 (10.7) 0.09 470 36.4 (10.9) 38.1 (10.7) 0.09
Age at symptom onset, years 481 28.3 (8.4) 28.7 (9.1) 0.65 456 28.2 (8.4) 28.6 (9.0) 0.65
Symptom duration, years 481 8.3 (9.2) 9.6 (9.8) 0.10 456 8.2 (9.2) 9.5 (9.8) 0.12
Diagnostic delay, years 480 4.7 (7.6) 6.0 (7.8) 0.005 455 4.7 (7.5) 6.0 (7.8) 0.01
HLA-B27 positive, % 453 76.5 67.0 0.03 430 77.0 68.2 0.05
Positive family history for spondyloarthritis, % 417 32.0 40.5 0.08 393 32.1 42.0 0.05
Prior sacroiliitis on MRI, % 477 52.9 58.7 0.23 453 53.9 58.5 0.34
BASDAI 430 4.6 (2.2) 5.3 (2.1) 0.003 412 4.6 (2.2) 5.1 (2.1) 0.02
• BASDAI 1 (fatigue) 436 4.7 (2.8) 6.0 (2.4) < 0.001 418 4.7 (2.8) 5.9 (2.4) < 0.001
• BASDAI 2 (back pain) 436 5.9 (2.7) 6.5 (2.5) 0.03 418 5.9 (2.7) 6.3 (2.5) 0.10
• BASDAI 3 (joint pain/swelling) 435 3.6 (3.1) 4.2 (3.1) 0.04 417 3.6 (3.1) 4.1 (3.1) 0.07
• BASDAI 4 (enthesitis) 433 4.2 (3.3) 5.0 (3.1) 0.02 415 4.2 (3.3) 4.8 (3.0) 0.04
• BASDAI 5 (intensity of morning stiffness) 434 5.2 (3.0) 5.4 (3.1) 0.65 416 5.3 (3.0) 5.2 (3.1) 0.96
• BASDAI 6 (duration of morning stiffness) 433 4.0 (2.9) 4.1 (2.9) 0.68 415 4.0 (2.9) 4.0 (2.9) 0.99
Physician Global Assessment 481 3.7 (2.2) 3.8 (2.0) 0.49 412 3.7 (2.2) 3.7 (2.0) 0.86
Patient Global Assessment 430 5.3 (2.9) 5.6 (2.8) 0.27 412 5.3 (2.9) 5.5 (2.8) 0.54
ASDAS 402 2.9 (1.0) 2.9 (0.9) 0.23 386 2.9 (1.0) 2.9 (0.9) 0.49
CRP (mg/l), median (IQR) 463 4.0 (1.0; 8.0) 4.0 (2.0; 8.0) 0.86 441 4.0 (1.1; 8.0) 4.0 (2.0; 8.0) 0.96
Elevated CRP, % 459 26.5 26.6 1.00 437 26.5 26.1 1.00
BASFI 435 2.8 (2.4) 3.1 (2.5) 0.16 416 2.8 (2.4) 2.9 (2.4) 0.54
BASMI 473 1.3 (1.4) 1.3 (1.3) 0.98 449 1.4 (1.4) 1.3 (1.2) 0.72
EQ-5D 431 61.4 (22.5) 59.7 (20.1) 0.34 412 61.3 (22.6) 61.2 (19.4) 0.78
IBP according to ASAS, % 462 80.5 77.3 0.43 437 80.6 77.0 0.41
Spinal MRI inflammation, % 476 26.9 24.9 0.67 452 26.9 23.6 0.45
Spinal radiographic changes, % 476 6.3 3.6 0.20 452 5.9 3.0 0.17
Current peripheral arthritis,% 489 35.8 39.2 0.46 464 36.0 38.9 0.57
Number of swollen joints 481 0.7 (1.9) 0.9 (2.3) 0.38 457 0.7 (1.9) 0.7 (1.8) 0.54
Current enthesitis, % 483 64.0 79.6 < 0.001 459 63.8 78.3 < 0.001
Modified MASES 481 1.9 (2.5) 3.2 (3.4) < 0.001 457 1.8 (2.5) 2.9 (3.1) < 0.001
Co-morbid fibromyalgia, % 307 2.7 13.1 < 0.001 – – – –
Dactylitis ever, % 492 10.9 11.4 0.89 468 10.6 12.0 0.66
Uveitis ever, % 434 18.1 13.1 0.18 410 18.4 12.9 0.14
Psoriasis ever, % 373 9.1 9.1 1.00 351 9.3 8.4 0.85
Inflammatory bowel disease ever, % 427 6.0 7.9 0.46 403 5.6 8.2 0.33
Taking NSAIDs, % 471 87.3 90.4 0.31 447 87.6 89.6 0.55
Taking methotrexate, % 495 5.2 10.2 0.04 470 5.3 9.9 0.08
Taking sulfasalazine, % 495 4.8 6.1 0.56 470 4.8 6.2 0.55
Taking TNFi, % 495 14.7 15.5 0.90 470 14.5 15.2 0.90
Ever TNFi, % 495 68.0 72.0 0.78 470 67.4 70.8 0.80
Current smoking, % 432 32.0 30.2 0.75 413 32.0 28.3 0.45
Body mass index 483 25.7 (3.9) 24.3 (4.5) < 0.001 458 25.6 (3.9) 24.1 (4.2) < 0.001
Education, % 462 0.46 440 0.52
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patients (73.6%) and in a comparable proportion of
women vs. men (72.9% vs. 74.4%, respectively). Baseline
characteristics of these patients (Table 3) were similar to
the findings in all nr-axSpA patients starting a TNFi
(Table 2). In response/tolerance analyses, an ASAS40 re-
sponse was achieved by 17% of women and 38% of men
(OR 0.34; 95% CI 0.12, 0.93; Table 4). ASAS40 responses
were even lower in women than in men after adjustment
for baseline differences in BASDAI, MASES, BMI and
diagnostic delay (OR 0.19; 95% CI 0.05, 0.61; Tables 4
and 5). A higher BMI was associated with a lower
ASAS40 response (Table 5). In contrast, higher BASDAI
levels were associated with a trend for better ASAS40 re-
sponse. Crude response analyses and adjusted analyses
for other outcomes confirmed these results (Table 4).
Comparable results were obtained in a sensitivity ana-
lysis of the response/tolerance analysis, excluding pa-
tients having stopped the TNFi because of other reasons
for discontinuation and imputing patients having discon-
tinued the TNFi due to remission as responders
(Table 6). All adjusted treatment responses were still sig-
nificantly lower in women in comparison to men in nr-
axSpA patients still on first TNFi at 1 year (completer
analysis; OR 0.25; 95% CI 0.06, 0.91; Tables 4 and 5).
Discussion
This real-life cohort of patients with nr-axSpA, with
classification performed after central reading of pelvis
radiographs, reveals less differences in demographics
and clinical manifestations between women and men
than previously found for the radiographic subgroup of
axSpA. Despite continuous efforts for early diagnosis,
diagnostic delay is, however, still considerable in nr-
axSpA (approximately 5 years) and significantly longer
(> 1 year) in women than in men. In contrast to r-
axSpA, age at symptom onset in female vs. male patients
is comparable in nr-axSpA [29]. Importantly, in contrast
to r-axSpA, there were no differences between the
genders with regard to important clinical parameters:
disease activity as assessed by the ASDAS; the propor-
tion of patients with elevated CRP; the level of CRP ele-
vation; the proportion of patients with sacroiliac joint
and spinal MRI inflammation; the presence of peripheral
arthritis and dactylitis; functional and mobility impair-
ments as assessed by the BASFI and BASMI, respect-
ively; health-related quality of life; and global assessment
of disease by patients or their rheumatologists. Despite
these similarities between the genders in nr-axSpA, re-
sponse to TNFi was significantly lower in women than
in men (ASAS40 response: OR 0.19; 95% CI 0.05, 0.62;
p = 0.009). This differences in ASAS40 response between
the genders is greater than the one found in r-axSpA in
our previous report (OR 0.44; 95% CI 0.21, 0.91; p =
0.03) [18]. The most important difference between men
and women in nr-axSpA related to the BASDAI, as a
patient-reported disease activity outcome. The amplitude
of this difference was slightly lowered by exclusion of
nr-axSpA patients with co-morbid fibromyalgia, which
was more commonly seen in women, confirming previ-
ous analyses [30–32]. We cannot entirely exclude the
possibility that diagnosis of concurrent fibromyalgia
might have been missed in some patients, as clinical dif-
ferentiation between enthesitis and allodynia of fibro-
myalgia might be challenging in clinical practice.
However, our results were adjusted for the remaining
differences in BASDAI and MASES. Moreover, a higher
prevalence of enthesitis in women compared to men has
consistently been shown in the radiographic disease
state, not excluding a potential phenotypic distinction
between the genders [33].
Less than 10% of women reached strict treatment re-
sponse criteria, such as the ASDAS major improvement
or remission criteria, while more than 25% of men with
nr-axSpA achieved these responses. Male sex was also
identified to be an important predictor of remission in
nr-axSpA patients treated with adalimumab in the open-
Table 1 Characteristics of all patients classified as having nonradiographic axial spondyloarthritis at inclusion in SCQM (Continued)











• Compulsory 15.8 19.8 15.2 18.3
• Vocational 56.7 51.8 57.4 52.4
• University 27.4 28.3 27.5 29.3
Absenteeism within last year, % 389 53.9 44.0 0.12 372 53.9 43.2 0.10
All patients with nr-axSpA are presented in A, while patients with co-morbid fibromyalgia are excluded in B. Except where indicated otherwise, values are the
mean (SD). Data in bold are statistically significant. ASAS Assessment of SpondyloArthritis international Society, ASDAS Ankylosing Spondylitis Disease Activity
Score, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis
Metrology Index, CRP C-reactive protein, EQ-5D EuroQol 5-domains, FM fibromyalgia, HLA-B27 human leucocyte antigen B27, IBP inflammatory back pain, MASES
Maastricht Ankylosing Spondylitis Enthesitis Score, modification refers to the inclusion of the plantar fascia in the count, MRI magnetic resonance imaging, nr-
axSpA nonradiographic axial spondyloarthritis, NSAIDs nonsteroidal anti-inflammatory drugs, TNFi tumor necrosis factor inhibitor
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label phase of a recent trial [27], as well as in a Danish
observational study investigating treatment response in
AS vs. nr-axSpA after adjustment for sex [8]. Our
current study therefore adds to available data to support
the claim for future randomized controlled trials in
axSpA to be sufficiently powered to detect potential sex
differences [33].
Some limitations of our current analyses have to be
acknowledged. Concern has arisen that since the
introduction of the ASAS axSpA classification criteria
misclassification or overtreatment might occur more
frequently, particularly in nr-axSpA [34, 35]. There is
increasing evidence that several imaging abnormalities
might mimic mild sacroiliitis on MRI and some of
these are more frequent in women (such as bone
more edema following pregnancy or associated with
osteitis condensans ilii) [36–38]. We were not able to
evaluate the extent of this potential imaging
Table 2 Characteristics of nr-axSpA patients at initiation of first TNFi treatment after exclusion of patients with co-morbid fibromyalgia
Parameter N, 163 Men, N = 78 Women, N = 85 p
Age, years 163 35.6 (10.8) 39.1 (11.4) 0.10
Age at onset, years 162 27.9 (8.6) 28.1 (8.5) 0.66
Symptom duration, years 163 7.6 (8.8) 10.9 (10.8) 0.05
Diagnostic delay, years 162 4.1 (7.6) 7.8 (9.9) 0.005
HLA-B27 positive, % 149 75.7 68.0 0.36
Prior sacroiliitis on MRI, % 154 70.8 68.3 0.86
BASDAI 148 5.3 (2.0) 6.3 (1.6) 0.003
Physician Global Assessment 155 5.0 (1.9) 4.8 (1.6) 0.63
Patient Global Assessment 149 6.4 (2.2) 6.7 (2.1) 0.30
ASDAS 140 3.3 (1.0) 3.4 (0.7) 0.29
ASDAS > 2.1, % 140 83.9 96.2 0.02
CRP (mg/l), median (IQR) 154 6.0 (2.0; 12.0) 5.0 (3.0; 9.0) 0.43
Elevated CRP, % 154 42.5 38.3 0.62
BASFI 148 3.6 (2.4) 3.8 (2.5) 0.54
BASMI 141 1.2 (1.1) 1.4 (1.2) 0.42
EQ-5D 141 54.8 (22.8) 55.8 (18.3) 0.79
Current periph. Arthritis,% 159 41.6 52.4 0.20
Number of swollen joints 155 0.7 (1.2) 1.3 (2.5) 0.32
Current enthesitis, % 158 80.5 85.2 0.53
Modified MASES 157 2.3 (2.5) 3.9 (3.3) 0.002
Dactylitis ever, % 161 13.2 21.2 0.21
csDMARDs ever, % 163 26.9 41.2 0.07
Taking NSAIDs, % 150 92.9 86.2 0.29
Current smoking, % 139 28.3 22.8 0.55
Body mass index 160 25.9 (4.2) 24.0 (4.4) < 0.001
Type of TNFi, % 163 0.25
• Adalimumab 34.6 45.9
• Certolizumab 1.3 0.0
• Etanercept 19.2 15.3
• Golimumab 20.5 24.7
• Infliximab 24.4 14.1
Except where indicated otherwise, values are the mean (SD). Data in bold are statistically significant. Patients with co-morbid fibromyalgia were excluded from
these analyses. ASDAS Ankylosing Spondylitis Disease Activity Score, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis
Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, CRP C-reactive protein levels; csDMARDs conventional synthetic disease-modifying anti-
rheumatic drugs, EQ-5D EuroQol 5-domains, HLA-B27 human leucocyte antigen B27, MASES Maastricht Ankylosing Spondylitis Enthesitis Score, modification refers
to the inclusion of the plantar fascia in the count, nr-axSpA nonradiographic axial spondyloarthritis, NSAIDs nonsteroidal anti-inflammatory drugs, TNFi tumor
necrosis factor inhibitor
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misinterpretation, as MRIs were not available for cen-
tral scoring. This also impeded the evaluation of po-
tential sex differences regarding the extent and the
intensity of sacroiliac joint inflammation in nr-axSpA
[39, 40]. With regard to potential misdiagnosis of
fibromyalgia as axSpA, it is important to note that
patients with fibromyalgia rarely fulfill classification
criteria for axSpA, as has recently been demonstrated
[41, 42]. We have excluded axSpA patients with con-
current fibromyalgia from the treatment effectiveness
Table 3 Characteristics of nr-axSpA patients at initiation of first TNFi treatment with available follow-up visit at 1 year (patients with
co-morbid fibromyalgia excluded)
Parameter A. Nr-axSpA patients with available follow-up visit
at 1 year
B. Nr-axSpA patients still on TNFi treatment
at 1 year
N, 120 Men, N = 58 Women, N = 62 p N, 83 Men, N = 45 Women, N = 38 p
Age, years 120 36.0 (10.8) 38.6 (11.4) 0.25 83 34.6 (10.3) 39.2 (13.4) 0.16
Age at onset, years 120 27.7 (8.4) 27.9 (8.2) 0.78 83 27.4 (8.0) 27.4 (7.5) 0.89
Symptom duration, years 120 8.3 (9.5) 10.7 (11.3) 0.27 83 7.2 (7.8) 11.7 (12.2) 0.12
Diagnostic delay, years 120 4.7 (8.6) 7.3 (10.1) 0.03 83 3.0 (5.3) 7.4 (10.3) 0.02
HLA-B27 positive, % 110 79.6 73.2 0.50 78 83.3 77.8 0.58
Prior sacroiliitis on MRI, % 112 67.9 67.8 1.00 77 66.7 65.7 1.00
BASDAI 108 5.4 (2.0) 6.1 (1.6) 0.05 74 5.2 (2.0) 5.9 (1.6) 0.09
Physician Global Assessment 115 5.1 (1.9) 4.8 (1.7) 0.54 81 5.3 (2.0) 4.7 (1.8) 0.28
Patient Global Assessment 109 6.6 (2.2) 6.7 (1.9) 1.00 75 6.5 (2.2) 6.4 (2.0) 0.89
ASDAS 100 3.4 (0.9) 3.4 (0.7) 0.63 69 3.4 (0.9) 3.4 (0.6) 0.90
ASDAS > 2.1, % 100 88.9 94.5 0.46 69 91.7 97.0 0.62
CRP (mg/l), median (IQR) 111 7.0 (2.0; 15.0) 7.0 (3.0; 10.0) 0.63 77 7.3 (3.0; 19.5) 7.0 (3.5; 10.5) 0.37
Elevated CRP, % 111 47.2 43.1 0.71 77 54.8 42.9 0.36
BASFI 109 3.7 (2.4) 3.5 (2.4) 0.61 75 3.5 (2.4) 3.2 (2.3) 0.53
BASMI 102 1.2 (1.1) 1.4 (1.2) 0.37 70 1.1 (1.1) 1.2 (1.3) 0.88
EQ-5D 103 53.7 (22.8) 57.6 (17.8) 0.52 70 55.6 (21.7) 59.2 (15.7) 0.65
Current periph. arthritis,% 116 47.4 47,5 1.00 82 46.7 54.0 0.66
Number of swollen joints 113 0.7 (1.2) 1.2 (2.6) 0.83 80 0.8 (1.3) 1.5 (2.9) 0.52
Current enthesitis, % 115 80.7 86.2 0.46 82 80.0 86.5 0.56
Modified MASES 114 2.4 (2.6) 3.7 (3.2) 0.02 81 2.1 (2.2) 3.4 (2.7) 0.03
Dactylitis ever, % 118 16.1 19.4 0.81 82 11.4 21.1 0.36
csDMARDs ever, % 120 31.0 40.3 0.34 83 26.7 36.8 0.35
Taking NSAIDs, % 109 94.1 86.2 0.21 76 100.0 85.7 0.02
Current smoking, % 102 28.9 15.8 0.15 68 26.5 8.8 0.11
Body mass index 120 25.9 (4.2) 24.0 (4.4) 0.002 83 25.6 (4.2) 23.6 (4.7) 0.004
Type of TNFi, % 120 0.69 83 0.38
• Adalimumab 34.5 43.5 35.6 50.0
• Certolizumab 1.7 0.0 2.2 0.0
• Etanercept 19.0 16.1 20.0 10.5
• Golimumab 22.4 24.2 20.0 26.3
• Infliximab 22.4 16.1 22.2 13.2
A is the characteristics of patients starting TNFi included in the response/tolerance analyses: response in patients with available outcome at 1 year, patients having
discontinued the first TNFi in the meantime being considered non-responders. B is the characteristics of patients starting TNFi included in the completer analyses
at 1 year. Except where indicated otherwise, values are the mean (SD). Data in bold are statistically significant. Patients with co-morbid fibromyalgia were
excluded from these analyses. ASDAS Ankylosing Spondylitis Disease Activity Score, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath
Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, CRP C-reactive protein levels, csDMARDs conventional synthetic
disease-modifying anti-rheumatic drugs, EQ-5D EuroQol 5-domains, HLA-B27 human leucocyte antigen B27, MASES Maastricht Ankylosing Spondylitis Enthesitis
Score, modification refers to the inclusion of the plantar fascia in the count, nr-axSpA nonradiographic axial spondyloarthritis, NSAIDs nonsteroidal anti-
inflammatory drugs, TNFi tumor necrosis factor inhibitor
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analyses, if its presence was either reported at start of
treatment or at any time-point during follow-up.
However, we might have missed some patients, as the
screening for fibromyalgia was based on the expert
opinion of the treating rheumatologist reported on a
comorbidity questionnaire and not through fulfillment
of classification criteria for fibromyalgia or via the use
of a standardized fibromyalgia questionnaire. The co-
morbidity form was available in 62% of the popula-
tion as the rheumatologist was led through it in the
online database before being able to enter the find-
ings of the clinical examination to help with its sys-
tematic completion. Given the fact that patients
treated with biologics are preferentially included in
SCQM, we expected a lower proportion of patients
with fibromyalgia in comparison to other axSpA stud-
ies, assuming that rheumatologists might be reluctant
to install biologics in axSpA patients diagnosed with
concurrent fibromyalgia.
We have found a lower proportion of HLA-B27 in
women as compared to men, as has also been reported
for the radiographic disease form in SCQM [18] as well
as in the US PSOAS cohort [12]. While genotypic differ-
ences between genders cannot be entirely excluded, this
finding might alternatively point to the possibility of a
higher misclassification rate in women. We have not ad-
justed our response analyses for HLA-B27 as the re-
spective proportions of positivity in men and women
Table 4 Clinical outcome of women versus men with nr-axSpA after 1 year of treatment with a first TNF inhibitor
Type of analysis Outcome Unadjusted analyses Adjusted analyses#
N Women % Men % OR 95% CI p N OR 95% CI p
Response/tolerance* ASAS20 99 27 57 0.28 0.11; 0.68 0.002 93 0.16 0.04; 0.50 0.003
ASAS40 99 17 38 0.34 0.12; 0.93 0.02 93 0.19 0.05; 0.62 0.009
BASDAI50 98 23 50 0.30 0.11; 0.77 0.007 93 0.19 0.05; 0.58 0.005
ASDAS improvement ≥ 1.1 84 28 58 0.29 0.10; 0.78 0.008 82 0.26 0.08; 0.75 0.02
ASDAS < 2.1 93 27 49 0.39 0.15; 1.00 0.03 86 0.18 0.04; 0.65 0.01
ASDAS improvement ≥ 2 84 4 26 0.13 0.01; 0.68 0.005 82 0.04 0.00; 0.27 0.003
ASDAS < 1.3 93 8 29 0.23 0.05; 0.82 0.01 86 0.07 0.01; 0.39 0.005
Completer** ASAS20 68 45 73 0.31 0.10; 0.94 0.03 66 0.15 0.03; 0.60 0.01
ASAS40 68 29 49 0.44 0.14; 1.31 0.14 66 0.25 0.06; 0.91 0.04
BASDAI50 67 39 64 0.36 0.12; 1.07 0.05 66 0.20 0.05; 0.75 0.02
ASDAS improvement ≥ 1.1 61 46 67 0.44 0.14; 1.38 0.13 60 0.36 0.09; 1.29 0.13
ASDAS < 2.1 67 43 59 0.53 0.18; 1.54 0.22 63 0.28 0.06; 1.12 0.08
ASDAS improvement ≥ 2 61 7 30 0.18 0.02; 0.98 0.03 60 0.05 0.00; 0.38 0.01
ASDAS < 1.3 67 13 35 0.29 0.06; 1.11 0.05 63 0.08 0.01; 0.47 0.01
*Response in patients with available outcome at 1 year, patients having discontinued the first TNFi in the meantime being considered non-responders. **Response
in patients still on their first TNFi at 1 year. Patients with co-morbid fibromyalgia were excluded from these analyses. #Adjustment for diagnostic delay, MASES,
BASDAI and BMI. ASAS20 and ASAS40 20% and 40% improvement according to the ASAS criteria, respectively; ASDAS Ankylosing Spondylitis Disease Activity Score;
BASDAI50 50% improvement in the BASDAI; nr-axSpA nonradiographic axial spondyloarthritis; TNF tumor necrosis factor
Table 5 Adjusted ASAS40 response of women versus men after 1 year of treatment with a first TNF inhibitor
Variable A. Response/tolerance analysis B. Completer analysis
OR 95% CI p OR 95% CI p
Female vs. male 0.19 0.05; 0.62 0.009 0.25 0.06; 0.91 0.04
Diagnostic delay 0.97 0.91; 1.03 0.41 0.98 0.90; 1.05 0.66
Modified MASES 0.82 0.61; 1.05 0.14 0.77 0.56; 1.02 0.08
BASDAI 1.24 0.91; 1.75 0.18 1.41 1.00; 2.08 0.06
BMI 0.78 0.64; 0.92 0.008 0.82 0.66; 0.97 0.04
A is the ASAS40 response in patients with available outcome at 1 year, patients having discontinued the first TNFi in the meantime being considered non-
responders. B is the ASAS40 response in patients still treated with the first TNF inhibitor at 1 year. Patients with co-morbid fibromyalgia were excluded from both
analyses. ASAS40 40% improvement according to the Assessment in SpondyloArthritis International Society criteria, BASDAI Bath Ankylosing Spondylitis Disease
Activity Index, BMI body mass index; CI confidence interval; MASES Maastricht Ankylosing Spondylitis Enthesitis Score, modification refers to the inclusion of the
plantar fascia in the count, OR odds ratio
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were comparable at start of treatment. This would indi-
cate that rheumatologists might have been more
confident of the axSpA diagnosis in women in the pres-
ence of HLA-B27 positivity in order to start TNFi treat-
ment. The proportion of patients with a positive family
history of spondyloarthritis was higher in women and
this difference might potentially involve recall bias.
Conclusion
Despite only few sex differences in baseline characteris-
tics of patients with nr-axSpA, a disease subgroup
known for its balanced sex ratio, response to treatment
with TNFi was significantly lower in women than in
men.
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